Cargando…
Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155032/ https://www.ncbi.nlm.nih.gov/pubmed/27499140 http://dx.doi.org/10.1038/leu.2016.221 |
| _version_ | 1782474930162499584 |
|---|---|
| author | Gadhoum, S Z Madhoun, N Y Abuelela, A F Merzaban, J S |
| author_facet | Gadhoum, S Z Madhoun, N Y Abuelela, A F Merzaban, J S |
| author_sort | Gadhoum, S Z |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5155032 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-51550322016-12-29 Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy Gadhoum, S Z Madhoun, N Y Abuelela, A F Merzaban, J S Leukemia Letter to the Editor Nature Publishing Group 2016-12 2016-09-13 /pmc/articles/PMC5155032/ /pubmed/27499140 http://dx.doi.org/10.1038/leu.2016.221 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Gadhoum, S Z Madhoun, N Y Abuelela, A F Merzaban, J S Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy |
| title | Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy |
| title_full | Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy |
| title_fullStr | Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy |
| title_full_unstemmed | Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy |
| title_short | Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy |
| title_sort | anti-cd44 antibodies inhibit both mtorc1 and mtorc2: a new rationale supporting cd44-induced aml differentiation therapy |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155032/ https://www.ncbi.nlm.nih.gov/pubmed/27499140 http://dx.doi.org/10.1038/leu.2016.221 |
| work_keys_str_mv | AT gadhoumsz anticd44antibodiesinhibitbothmtorc1andmtorc2anewrationalesupportingcd44inducedamldifferentiationtherapy AT madhounny anticd44antibodiesinhibitbothmtorc1andmtorc2anewrationalesupportingcd44inducedamldifferentiationtherapy AT abuelelaaf anticd44antibodiesinhibitbothmtorc1andmtorc2anewrationalesupportingcd44inducedamldifferentiationtherapy AT merzabanjs anticd44antibodiesinhibitbothmtorc1andmtorc2anewrationalesupportingcd44inducedamldifferentiationtherapy |